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Abstract: The incidence of esophagogastric cancers is increasing rapidly in the Western 
population. Despite better understanding of the biology and intense research in the treatment of 
these cancers, the long-term survival remains poor both in the locally advanced and metastatic 
settings. The addition of combined modality strategies has resulted in modest improvement in 
5-year survival rates. A number of biologic agents targeting epidermal-derived growth factor 
receptor, vascular endothelial derived growth factor and its receptor, and mammalian target 
of rapamycin (mTOR) are being currently evaluated in Phase II and III clinical trials. Some 
of these, like trastuzumab, cetuximab, and bevacizumab, have shown promising results. This 
review provides a brief overview of the recent developments in biologic agents for the treat-
ment of esophagogastric cancers.
Keywords: adenocarcinoma, squamous cell carcinoma, VEGF, trastuzumab, Her2- 
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Introduction
Esophagogastric cancers (EGCs) include tumors involving the esophagus, gastroe-
sophageal junction (GEJ), and stomach. While the tumors involving the esophagus 
can be of either adenocarcinoma (AC) or squamous cell carcinoma (SCC) histology, 
tumors involving the GEJ and stomach are almost exclusively of AC type. The EGCs 
constitute a significant problem worldwide. The incidence of EGC-AC is increasing 
rapidly in the Western population.1 There are demographic variations in the incidence 
of these tumors, and there has been a major change in the epidemiological trend towards 
AC histological subtype in the Western world over the last two decades.2–4 Globally, 
SCC is still the most common subtype of esophageal cancer, but AC is now the most 
prevalent in the West.
Despite greater understanding of the biology and intense research in the treat-
ment of EGC, the prognosis and long-term survival remains poor for both locally 
advanced and metastatic disease, with a case–fatality ratio of 84% (esophageal) 
and 75%   (gastric), respectively.5 Current treatment options for locally advanced 
disease include surgery alone, combined modality treatment (perioperative chemo-
radiotherapy, or chemotherapy), or definitive chemoradiation therapy. The 5-year 
survival rates for locally advanced disease with surgery alone are only 20%–25%.6,7 
Poor outcomes with surgery alone have led to the evaluation of combined   modality 
approaches to improve the survival. Such therapy has now become the standard 
of care for locally advanced disease. However, the addition of combined modality 
  strategies results in modest improvement in 5-year survival rates to only 30%–35%.7–10 
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Palliative   chemotherapy is the current treatment approach 
practiced by medical oncologists worldwide for metastatic 
disease. The objective response rate (ORR) with palliative 
chemotherapy for metastatic disease is only 20%–40%, with 
a median overall survival (OS) of 8–10 months.11 Various 
combination chemotherapy regimens have been used with 
addition of a third drug but have achieved a modest benefit 
only at the cost of increased toxicity in this cohort of patients 
with increased comorbidites.12,13
The lack of any further significant benefit in OS and ORR 
with cytotoxic chemotherapy seems unlikely though not 
impossible and has lead investigators to believe that a plateau 
has been reached. Therefore, in the era of intense transla-
tional research and personalized therapy, the focus of current 
clinical trials has shifted to integrating molecular targeted 
therapies into current treatment strategies and to exploiting 
the molecular abnormalities that are involved in the etiology 
and pathogenesis of these tumors. The molecular targets 
currently being evaluated in various Phase II and III clinical 
trials include the epidermal-derived growth factor recep-
tor (EGFR) with subtypes ERBB-1, ERBB-2 (Her2/neu), 
ERBB-3 and ERBB-4, vascular endothelial derived growth 
factor (VEGF) and its receptor (VEGFR), and mammalian 
target of rapamycin (mTOR). The focus of this review is to 
evaluate the current evidence for molecular-targeted agents 
in the management of EGC.
Potential targets and biologic agents
HER2/neu tyrosine kinase receptor
Her2/neu is a member of the ERBB tyrosine kinase (TK) 
receptor family. Peptide ligands bind to its extracellular 
domain, leading to receptor homo- and hetero-dimerization 
followed by auto-phosphorylation of the kinase. Her2/neu 
has been variably expressed in EGC (AC) (mean 23%; 
range 0%–43%).14,15 Approximately 25% of advanced gas-
tric cancers (GCs) (similar to breast cancer) overexpress 
Her2/neu.16–18 This variability is presumably related to the dif-
ferences in Her2/neu testing based on   immunohistochemistry 
(IHC) or fluorescent in-situ hybridization (FISH) and dif-
ferent stages of disease. Her2 positivity is more common in 
the intestinal type and EGC rather than the diffuse type and 
pure GC.19–21 Her2 amplification on FISH is an independent 
prognostic factor which correlates with the depth of invasion, 
nodal/distant metastasis, and poor survival.21–23 There is high 
concordance observed between HER2 results obtained by 
both IHC and FISH on primary tumors and corresponding 
metastases.24
Anti-Her2/neu monoclonal antibody 
(trastuzumab)
Trastuzumab (Herceptin®, Genentech, South San Francisco, 
CA) is a humanized IgG1 monoclonal antibody targeting 
the Her2/neu receptor. It acts through several mechanisms, 
including inhibition of receptor dimerization, increasing 
receptor endocytosis and degradation, and inducing anti-
body dependent cytotoxicity.25 Trastuzumab is approved 
by the United States Food and Drug Administration (FDA) 
for the treatment of breast cancer, both in the adjuvant and 
metastatic settings.26–29
Safran et al30 did a Phase I/II study (n = 19) of trastu-
zumab in combination with cisplatin and paclitaxel in locally 
advanced, HER2 overexpressing, esophageal adenocarci-
noma. The ORR was 43%, with an OS of 24 months. The 
2-year survival was 50%. There was no significant cardio-
toxicity related to trastuzumab.
Recently, Bang et al31 published the results of the 
Phase III ToGA (Trastuzumab for GC) trial of   capecitabine/ 
5-  fluorouracil (5-FU) and cispaltin with or without 
  trastuzumab. This was an open-label, international, Phase III, 
randomized controlled trial and included patients with 
Her2 overexpressing (by IHC or FISH) GC or GEJ tumors. 
  Participants were randomly allocated in a 1:1 ratio to receive 
a chemotherapy regimen (capecitabine/5-FU plus cisplatin 
given every 3 weeks for six cycles) or the same chemotherapy 
in combination with intravenous trastuzumab. Out of a total 
of 3807 patients whose tumors were assessed for Her2 posi-
tivity, 22.1% were Her2 positive and 594 were randomized. 
Median follow-up was 18.6 months in the trastuzumab plus 
chemotherapy group and 17.1 months in the chemotherapy 
alone group. There was a statistically significant increase in 
ORR in the trastuzumab-containing arm compared with the 
chemotherapy alone arm (47.3% versus 34.5%; P = 0.0017). 
The median progression-free survival (PFS) (6.7 versus 
5.5 months, hazard ratio [HR] 0.71, 95% confidence interval 
[CI] 0.59–0.85; P = 0.0002) and OS (13.8 months versus 
11.1 months P = 0.0046, HR = 0.74, 95% CI 0.60–0.91) were 
also in favor of the trastuzumab-containing arm compared 
with the chemotherapy alone arm.
In an exploratory post-hoc analysis, the OS was longer 
in patients with high expression of Her2 compared with 
those with low Her2 expression.31 This analysis suggested 
that in patients with the highest levels of HER2 protein 
expression (HER2 2+ and FISH positive, HER2 3+ and 
FISH positive), trastuzumab conferred an even greater 
survival benefit than that observed for the intention-to-
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treat population (16.0 versus 11.8 months; HR 0.65). This 
treatment combination is the first to result in a median sur-
vival beyond 1 year and will change the standard of care for 
HER2-positive GC. Based on these data, trastuzumab has 
been approved for the treatment of HER2-positive advanced 
GC in combination with chemotherapy in several countries, 
including in Australia where it is approved (but not yet 
subsidized) for first-line HER2-positive advanced GC/GEJ 
cancers in combination with cisplatin, and either 5-FU or 
capecitabine. The data suggests that trastuzumab is more 
effective in the subgroup of patients with IHC 3+ tumors 
(HR 0.66, 95% CI 0.50–0.87) compared with patients with 
IHC 2+ tumors (HR 0.78, 95% CI 0.55–1.10). There was 
also no unexpected toxicity in the trastuzumab arm including 
symptomatic heart failure; however, there was an increased 
incidence of asymptomatic decrease in ejection fraction 
(4.6% versus 1.1%). The quality of life was not compromised 
in the trastuzumab arm in a recent analysis.32 Future research 
should focus on evaluating the role of trastuzumab beyond 
progression and locally advanced (neo-adjuvant/adjuvant) 
settings. The pattern of HER2 amplification/overexpression 
in GC tissue (heterogeneous and frequently focal), and the 
scoring system used to assess it, differ from that in breast 
cancer, and consequently, HER2 testing protocols used for 
breast cancer specimens require modification to be used for 
GC specimens.33,34
Anti-Her2/neu tyrosine kinase  
inhibitor (lapatinib)
Lapatinib (Tykerb®, GlaxoSmithKline, London, UK) is an 
orally active, dual TK inhibitor (TKI) with activity against 
both EGFR (ERBB1) and Her2 (ERBB2). Two Phase II 
trials have evaluated the role of lapatinib in EGC, but the 
results have been disappointing. The Southwest Oncology 
Group (SWOG) performed a Phase II study evaluating the 
role of lapatinib as monotherapy in the first-line setting 
in advanced GC patients (n = 47).35 The partial response 
rate was only 7%, with a median time to treatment   failure 
and OS of 2 and 5 months respectively. In the second 
Phase II study, 25 patients with pretreated Her2-positive 
EGC (through IHC or FISH) were evaluated.36 The ORR 
was 0% in 21   evaluable patients, with two patients having 
stable disease for 5 and 9 months.
Despite the poor ORR from Phase II studies, two Phase III 
studies are evaluating the role of lapatinib in conjunction with 
chemotherapy: LOGIC Trial (lapatinib in combination with 
capecitabine and oxaliplatin as first line) and TYTAN trial 
(lapatinib in combination with weekly paclitaxel as second 
line). The clinical trials of anti-Her2/neu agents in EGC are 
summarized in Table 1.
EGFR
EGFR (or ERBB1) is a member of the ERBB TK receptors. 
Ligand binding to the extracellular domain of the TK recep-
tor leads to its activation and subsequent homo-dimerization, 
  followed by auto-phosphorylation of the intracellular sig-
naling cascade including RAS/RAF/MAP kinase pathway. 
These pathways play an important role in angiogenesis, cell 
survival and proliferation, apoptosis, and metastasis.
Abnormal expression and activating mutations of EGFR 
have been reported in EGC, eg, EGFR overexpression 
by IHC/SISH occurs in 50%–63% of patients with GC.37 
  Overexpression of EGFR is a poor prognostic indicator in 
EGC with poorly differentiated histology, depth of inva-
sion, and shorter survival.38 EGFR overexpression is more 
  commonly associated with SCC histology than AC.
Table 1 Clinical trials of anti-Her2/neu agents in EGC
Author Phase Histology Stage Treatment No of  
patients
ORR or  
pCR rate
TTP/PFS 
(months)
OS 
(months)
Bang  
et al31
iii AC LA (20) 
Met (584)
5-FU/capecitabine + cisplatin 
versus 
5-FU/capecitabine + cisplatin +  
trastuzumab
290  
versus 
294
34.5% 
versus 
47.3%
5.5 
versus 
6.7
11.1 
versus 
13.8
Safran  
et al30
i/ii AC LA Trastuzumab + cisplatin/ 
paclitaxel/RT
19 43% NS 24
iqbal  
et al35
ii AC Met Lapatinib 47 7% 2 5
Hecht  
et al36
ii AC Met Lapatinib 25 0% NS NS
Abbreviations: 5-FU, 5-fluorouracil; EGC, esophagogastric cancer; NS, not stated; ORR, overall response rate; TTP, time to progression; PFS, progression-free survival; 
OS, overall survival; pCR, pathological complete response; AC, adenocarcinoma; LA, locally advanced; Met, metastatic; RT, radiotherapy.
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Another oncogene downstream of EGFR is KRAS. 
The predictive value of KRAS status to anti-EGFR therapy 
has been well validated in metastatic colorectal cancer.39,40 
At present, none of the trials evaluating the EGFR-targeted 
therapies are restricted to patients with wild-type KRAS 
tumors, as the frequency of KRAS mutations in GC is 
expected to be low (around 5%),41 and there are currently 
no data to suggest that KRAS gene mutation is predictive 
of lack of response to EGFR-targeted monoclonal antibody 
therapy in this tumor type.
Anti-EGFR monoclonal antibodies
Cetuximab
Cetuximab (Erbitux®, ImClone Systems, New York, NY) 
is a partially humanized murine IgG1 monoclonal antibody 
that blocks the binding of protein ligands to the EGFR and 
its activation.42 Various other proposed mechanisms of 
action of cetuximab include receptor internalization through 
  endocytosis and immune-mediated mechanisms including 
antibody-dependent cytotoxicity, complement-dependent 
cytotoxicity, and complement-dependent cell-mediated 
cytotoxicity.43,44 It is currently FDA approved in the man-
agement of metastatic colorectal cancer as monotherapy or 
combination therapy and in conjunction with radiotherapy 
(RT) in the management of head and neck SCC.45,46
Cetuximab is the most extensively studied anti-EGFR 
monoclonal antibody in the management of EGC, both 
in the locally advanced and metastatic settings as first- or 
second-line therapy. Cetuximab has been evaluated in the 
locally advanced setting in six clinical trials. It has been 
used in combination with various cytotoxic regimens and 
RT preoperatively (4/6),47–50 monotherapy with RT preop-
eratively (1/6),51 and in combination with cytotoxic therapy 
and RT both preoperatively and postoperatively (1/6).52 The 
results from these trials should be interpreted with caution as 
the findings are preliminary and time to progression (TTP) 
and OS data are awaited. The ORR/pathological complete 
response (pCR) rates range from 13%–40% across these 
  trials. The results have been summarized in Table 2. With 
the exception of the trial by Ma et al52 (100% grade 3/4 
  serious adverse event rate and lower pCR), the toxicity pro-
file in these trials have been consistent with other combined 
chemoradiotherapy trials.
Cetuximab has been evaluated in the first-line metastatic 
setting in combination with other cytotoxic therapies in 
numerous trials. The chemotherapy backbone used in these 
trials includes FOLFIRI (two weekly bolus 5-FU/  leucovorin/
irinotecan and infusional 5-FU),53 5-FU/cisplatin,54   continuous 
infusion high-dose 5-FU/leucovorin/cisplatin,55 capecitabine/
cisplatin,56 cisplatin/docetaxel,57 oxaliplatin/irinotecan,58 
FUFOX (weekly oxaliplatin/leucovorin/  infusional 5-FU),59 
FUFIRI regimen (weekly irinotecan/infusional 5-FU/
leucovorin),60 and mFOLFOX.61 The results of these trials 
are summarized in Table 3. These results are promising, 
with ORR of 40%–69%, TTP 5.0–8.5 months, and OS of 
9.5–17.0 months across these eight trials. The toxicity in these 
trials has been consistent with known side-effect profiles of 
the chemotherapy backbone used, along with additive toxicity 
from cetuximab (grade 3/4: diarrhea 4%–33%, skin toxicity 
6%–24%, infusion reactions/anaphylaxis , 5%).
Tumor overexpression of EGFR has been associated 
with a poorer prognosis in GC.62 Overexpression of EGFR 
by IHC/SISH was not a prerequisite for most of these trials, 
except the trial by Pinto et al.53 Therefore, the impact of 
EGFR positivity on response remains unclear. Even in the 
study by Pinto et al,53 evaluating the combination of FOLFIRI 
and cetuximab, there was no correlation between the degree 
of EGFR positivity and treatment response. Similar results 
were also noted by Lordick et al59 when they evaluated a 
combination of cetuximab with 5-FU/leucovorin/oxaliplatin 
(FUFOX). In contrast, Han et al61 in their trial of cetuximab 
in combination with modified 5-FU/leucovorin/oxaliplatin 
(mFOLFOX-6), noted that patients with EGFR-positive 
tumors and low EGF/TGF alpha levels (n = 11) had an ORR 
of 100% compared with only 37% in the remaining patients 
(n = 27) with EGFR-negative tumors (P # 0.001).
The studies evaluating combination of cetuximab with 
other chemotherapeutic agents in previously treated EGC 
have been disappointing, with the best ORR of only 11% 
in the SWOG study.63–65 These studies are summarized 
in Table 3. Currently, cetuximab is being evaluated in an 
open-label Phase III study in combination with capecitabine 
and cisplatin versus capecitabine/cisplatin alone (EXPAND- 
NCT00678535; Phase III; CX +/− cetuximab) as a first-line 
therapy in the management of advanced GC/GEJ AC.
Panitumumab
Panitumumab (Vectibix®, Amgen, Thousand Oaks, CA) is a 
fully humanized IgG2 anti-EGFR monoclonal antibody. It is 
currently FDA approved for the management of metastatic 
colorectal cancer.66 It has not been evaluated as extensively as 
cetuximab in the management of EGC; however, a Phase III 
study is being conducted in the UK to determine whether add-
ing panitumumab to epirubicin, oxalipaltin, and capecitabine 
(EOX) prolongs OS (REAL3 – NCT00824785; Phase III; 
EOX +/− panitumumab). Another study   currently open 
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Table 2 Clinical trials of cetuximab in EGC 
Author Phase Histology Stage Treatment No of 
patients
ORR or  
pCR rate
TTP/PFS 
(months)
OS 
(months)
Enzinger  
et al47
ii AC LA Cetuximab + cisplatin/ 
irinotecan/RT
17 13% NS NS
Safran  
et al48
ii AC/SCC LA Cetuximab + carbolatin/ 
paclitaxel/RT
60 27% NS NS
Ruhstaller 
et al50
ii AC/SCC LA Cetuximab + cisplatin/ 
docetaxel/RT
28 32% NS NS
De vita  
et al49
ii AC/SCC LA Cetuximab + FOLFOX/RT 27 40% NS NS
Agrawala  
et al51
ii AC/SCC LA Cetuximab + RT 40 36% NS NS
Ma et al52 ii AC LA Cetuximab + cisplatin/irinotecan + 
surgery → Cetuximab +  
5-FU/Lv/RT
20 0% NS NS
Lordick  
et al59
ii AC Met Cetuximab + FUFOX 52 65 
(of 46)
7.6 9.5
Pinto  
et al57
ii AC Met Cetuximab + cisplatin/docetaxel 48 41 
(of 42)
NS NS
Zhang  
et al56
ii AC Met Cetuximab + cisplatin/ 
capecitabine
49 48 
(of 47)
5.2 NS
Han et al61 ii AC Met Cetuximab + FOLFOX 40 50 5.5 9.9
Yeh et al55 ii AC Met Cetuximab + high dose 5-FU/Lv/ 
cisplatin
35 69 11 14
woell  
et al58
ii AC Met Cetuximab + oxaliplatin/ 
irinotecan
51 63% (of 35) 6.2 9.5
Lorenzen  
et al54
ii SCC Met Cetuximab + 5-FU/cisplatin 
versus 
5-FU/cisplatin
32 
versus 
30
19% 
versus  
13%
5.7 
versus 
3.6
9.5 
versus 
5.5
Pinto  
et al53
ii AC Met/UR Cetuximab + FOLFiRi  
(FOLCETUX)
38 44% (of 34) 8 16
Kanzler  
et al60
ii AC Met Cetuximab + FUFiRi 49 42% (of 48) 8.5 16.6
Abbreviations: EGC, esophagogastric cancer; 5-FU, 5-fluorouracil; FOLFIRI, two weekly bolus 5-FU/leucovorin, irinotecan, infusional 5-FU; FUFIRI, weekly irinotecan/
leucovorin/infusional; 5-FU FUFOX, weekly oxaliplatin/leucovorin/infusional 5-FU; Lv, leucovorin; RT, radiation therapy; NS, not stated; ORR, overall response rate; 
TTP, time to progression; PFS, progression-free survival; OS, overall survival; pCR, pathological complete response; AC, adenocarcinoma; SCC, squamous cell carcinoma; 
LA, locally advanced; Met, metastatic; UR, unresectable.
Table 3 Clinical trials of anti-vEGF agents
Author Phase Histology Stage Treatment No of  
patients
ORR or  
pCR rate
TTP/PFS 
(months)
OS 
(months)
Ohtsu et al88 iii AC Met/UR 5-FU/capecitabine + cisplatin +  
placebo 
versus 
5-FU/capecitabine + cisplatin +  
bevacizumab
387 
versus 
387
29.5% 
versus 
38%
5.3 
versus 
6.7
10.1 
versus 
12.1
Shah et al84 i/ii AC Met Bevacizumab + cisplatin/irinotecan 47 65% 8.3 12.3
Kelsen et al86 ii AC Met Bevacizumab + docetaxel/ 
cisplatin/5-FU
44 67% (of 37) 12 16.2
Enzinger et al87 ii AC/SCC Met Bevacizumab + docetaxel/cisplatin/ 
irinotecan
32 63% (of 30) NS NS
Bang et al91 ii AC Met Sunitinib 42 2.6% 2.3 6.8
Sun et al95 ii AC Met/UR Sorafenib + docetaxel/cisplatin 44 38.5% 5.8 14.9
Abbreviations: 5-FU, 5-fluorouracil; NS, no stated; ORR, overall response rate; TTP, time to progression; PFS, progression-free survival; OS, overall survival; pCR, pathological 
complete response; AC, adenocarcinoma; SCC, squamous cell carcinoma; LA, locally advanced; Met, metastatic; UR, unresectable; vEGF, vascular endothelial derived 
growth factor.
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to recruitment (NEOPECX) is an open-label   randomized 
controlled Phase II trial of panitumumabin in combination 
with epirubicin, cisplatin, and capecitabine (ECX) versus 
chemotherapy alone in patients with locally advanced 
GC/GEJ tumors.
Matuzumab
Matuzumab (EMD 72000, Merck) is a humanized   monoclonal 
antibody targeting the EGFR. It has been evaluated in a 
Phase I study in combination with epirubicin, cisplatin, and 
capecitabine (ECX) as a first-line therapy for patients with 
EGFR-positive EGC.67 The response to different doses of 
matuzumab was 57% (four partial responses and two stable 
disease) with 400 mg and 43% (three partial responses and 
two stable disease) with 800 mg. The major dose limiting 
toxicity was grade 3 fatigue. A Phase II study looking at a 
combination of matuzumab and ECX has recently completed 
recruitment (MATRIX EG).
Anti- EGFR tyrosine kinase inhibitors
Erlotinib
Erlotinib (Tarceva®, Genentech) is an oral small molecule 
TKI. It inhibits the binding of adenosine triphosphate to the 
TK domain of the EGFR, leading to cessation of downstream 
autophosphorylation and signal transduction. It is currently 
FDA approved for the management of advanced non-small 
cell lung cancer and pancreatic cancer.68,69
A Phase II study conducted by the SWOG evaluated 
erlotinib in the first-line setting in the management of GC 
(n = 26) and GEJ tumors (n = 44).70 There were no responses 
in the GC patients, and the ORR was only 9% (one complete 
response and two partial responses) in the GEJ tumors. The 
reason for the apparent differential sensitivity of GEJ and 
GC to EGFR blockade using erlotinib is unclear.
The TTF and OS were 2 months and 6.7 months respec-
tively in the GEJ tumor group. No EGFR gene mutation was 
detected in the 54 samples analyzed in this trial.
Gefitinib
Gefitinib (Iressa®, AstraZeneca Pharmaceuticals, London, UK) 
is another oral small molecule TKI. It is currently approved in 
the management of advanced non-small cell lung cancer.71
Rodriguez et al84 assessed the efficacy of gefitinib in 
combination with cisplatin/5-FU and RT (n = 80) to chemo-
RT alone (n = 93) in a Phase II trial of patients with EGC. 
There was a trend towards improved 3-year OS rates in favor 
of gefitinib arm (40% versus 28%; P = 0.07). Toxicity profiles 
were similar in both the arms.
In another Phase II study, gefitinib was evaluated in the 
second-line setting in 28 patients.72 The partial response 
rate was 3% and stable disease in 28%. The TTP and OS 
were 2.0 and 5.5 months respectively. There was a nonsig-
nificant trend towards improved outcome in patients with 
high EGFR expression compared with low EGFR expres-
sion (TTP 5.1 months versus 1.8 months and OS 7.8 months 
versus 2.8 months).73
In all the trials of oral TKIs as monotherapy or combina-
tion therapy, there has been no significant additional toxicity 
associated with the use of TKIs. However, they have limited 
activity as monotherapy in both the first- and second-line set-
ting in the management of EGC. From the available evidence, 
it seems that patients with squamous histology, high EGFR 
expression, and esophageal/GEJ tumors are more likely to 
have any meaningful response to TKIs, but these tumors are 
rarely of squamous type.
VEGFR
Our increasing understanding of the pathogenesis of tumor 
biology in most solid tumors has led us to believe that there 
is a strong link between tumor growth, distant metastasis, 
and angiogenesis.74 VEGF is the most potent and specific 
pro-angiogenic factor regulating endothelial cell mitogenesis 
and migration, induction of proteinases, increased vascular 
permeability, and maintaining survival of newly formed 
blood vessels.75 It exerts its angiogenic effect by binding to 
various transmembrane receptors, more specifically VEGFRs 
type 1 (VEGFR-1) and 2 (VEGFR-2).76
VEGF is overexpressed in 30%–60% of EGCs, and 
elevated levels of VEGF in the serum and tumor are associ-
ated with poor prognosis in EGCs.77–81 There is also evidence 
to support in esophageal AC that higher VEGF expression 
correlates with transition from Barrett’s esophagus to high 
grade dysplasia and from micro-invasive disease to locally 
advanced cancer.82,83
Anti-vEGF monoclonal antibodies
Bevacizumab
Bevacizumab (Avastin®, Genentech) is a humanized 
IgG1 monoclonal antibody-targeting VEGF. It is currently 
FDA approved for the management of advanced colorectal 
cancer, non-small cell lung cancer, glioblastoma multiforme, 
and metastatic renal cell carcinoma.
Multiple Phase II studies have looked at the role of 
bevacizumab in combination with chemotherapy as the ini-
tial treatment for patients with advanced GC/GEJ tumors. 
The early results from these studies have been encouraging. 
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Shah et al85 from Memorial Sloan-Kettering Cancer Centre 
(MSKCC) looked at a combination of bevacizumab with 
cisplatin and irinotecan in the first-line management of 
advanced GC/GEJ AC (n = 47). The results were encourag-
ing, with an ORR 65%, TTP 8.3 months (compared with TTP 
in historical controls of 5 months) and OS of 12.3 months. 
Toxicities related to the use of bevacizumab were: gastric 
perforation/near perforation 6%, myocardial infarction 2%, 
grade 3/4 thromboembolic events 25.5%.86 The same group 
from MSKCC also evaluated bevacizumab in combination 
with a modified regimen of docetaxel/cisplatin/5-FU (mDCF) 
in chemo-naïve patients (n = 44) and reported ORR of 67%, 
PFS of 12 months, and OS of 16.2 months in 39 patients with 
measurable disease.87 The toxicity profile of the mDCF was 
better than the original DCF,13 with febrile neutropenia rates 
of 4% versus 29% respectively. The side effects attributed 
to bevacizumab included: grade 3/4 thromboembolism 31% 
and gastric perforation/bleeding 2%. The studies evaluating 
bevacizumab in the first-line setting in combination with 
chemotherapy are summarized in Table 3.
Bevacizumab has also been tested in the second-line 
setting in a small study by Enzinger et al88 in combination 
with docetaxel. The ORR was 24% (17 patients evaluated). 
Bevacizumab-attributed grade 3/4 serious adverse events 
(SAEs) included: gastrointestinal bleeding (12%) and arte-
rial thrombosis (8%).
Due to the encouraging results with bevacizumab in 
conjunction with chemotherapy, both in the first- and second-
line settings, a confirmatory Phase III trial (AVAGAST) 
was   conducted.89 The AVAGAST trial was a multinational, 
randomized, placebo-controlled trial designed to evaluate the 
efficacy of bevacizumab in combination with capecitabine/cis-
platin in the first-line treatment of advanced GC/GEJ tumors 
(n = 774). The OS (primary end point) was 12.1 months 
with bevacizumab plus capecitabine/5-FU-cisplatin and 
10.1 months with placebo plus capecitabine/5-FU-cisplatin 
(HR 0.87; 95% CI, 0.73–1.03; P = 0.1002). Although the 
primary endpoint (OS) was not met, both ORR (46.0% versus 
37.4%; P = 0.0315) and median PFS (6.7 versus 5.3 months; 
HR 0.80; 95% CI, 0.68–0.93; P = 0.0037) were significantly 
improved with bevacizumab versus placebo. The incidence 
of venous and arterial thrombosis did not differ between the 
two groups. Although the rates of hypertension and bleeding 
were slightly higher in the bevacizumab arm, most of the 
bleeding was grade 1 nasal bleeding.
There were significant regional differences in the outcome 
in an unplanned subset analysis. The Asian population had 
the longest OS (12.1 months), but the smallest impact from 
addition of bevacizumab (HR, 0.97; 95% CI, 0.75–1.25) 
compared with the Pan-American population (which contrib-
uted only one-fifth of patients to the whole group) who had 
the shortest OS (6.8 months) but the greatest impact from 
addition of bevacizumab (median, 11.5 versus 6.8 months for 
placebo-chemotherapy; HR, 0.63; 95% CI, 0.43–0.94). The 
potential explanations forwarded for these differences were 
that the Asian population had low incidence of junctional 
tumors, low frequency of liver metastases, and a higher 
proportion of them received second-line chemotherapy com-
pared with the American group (66% versus 21%).
In the UK, another Phase III study [Medical Research 
Council Adjuvant Gastric Infusional Chemotherapy trial 
(MAGIC)-B] is currently recruiting patients to determine the 
efficacy of adding bevacizumab to chemotherapy (ECX) in 
the peri-operative setting.
Ramucirumab
Ramucirumab (IMC-1121B, ImClone Systems Corporation) 
is a fully humanized, IgG1 monoclonal antibody targeting 
VEGFR-2. It is currently being tested in a randomized, 
double-blind placebo-controlled trial in patients with meta-
static GC/GEJ AC who have failed first-line chemotherapy 
with a platinum agent or fluoropyrimidine.
Anti-vEGF TKis
Three anti-VEGF TKIs have been evaluated in EGC: suni-
tinib, sorafenib, telatinib.
Sunitinib
Sunitinib (Sutent®, Pfizer, New York, NY) is an oral multi-
targeted TKI with activity against VEGFR, platelet derived 
growth factor (PDGFR), RET, c-kit, and Flt-3. It is currently 
FDA approved for the treatment of metastatic renal cell car-
cinoma and gastrointestinal stromal tumors.90,91
Sunitinib has been tested in two Phase II trials. Bang et al92 
evaluated sunitinib as a second-line therapy in advanced 
GC/GEJ AC. Two patients had a partial response, and 25 
had stable disease with PFS and OS of 2.3 and 6.8 months 
  respectively. Moehler et al93 also examined sunitinib in previ-
ously treated GC and reported disease control in 5/14 patients. 
The toxicity with sunitinib was manageable in both these 
studies, with the common SAEs being thrombocytopenia, 
anorexia, nausea, and fatigue.
Sorafenib
Sorafenib (Nexavar®, Bayer, Leverkusen, Germany) is 
another oral multikinase inhibitor, with activity against both 
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intracellular RAF-kinases (CRAF, BRAF) and cell surface 
kinase receptors (VEGFR-1 to 3, PDGFR-beta, RET, Flt-3, 
and c-kit). It is currently FDA approved for advanced renal 
cell carcinoma and hepato-cellular carcinoma.94,95
Sorafenib has been tested by the Eastern Cooperative 
Oncology group (ECOG) in a Phase II study in combina-
tion with cisplatin/docetaxel (n = 44) in the management 
of metastatic/unresectable GC/GEJ AC.96 The results were 
encouraging, with an ORR of 38.5%, TTP of 5.8 months, 
and OS of 14.9 months. Grade 3 or 4 neutropenia occurred 
in 49% of patients.
Telatinib
Telatinib is also an oral small molecule TKI with selective 
inhibitory effect against VEGFR and PDGFR. It is not 
currently FDA approved. Ko et al97 conducted a Phase II 
study of telatinib in combination with capecitabine/cisplatin 
as first-line treatment in patients with advanced GC/GEJ 
tumors. The best response in the seven patients evaluated 
included two with partial response and four with stable 
disease. One patient progressed while on treatment. Grade 
3 SAEs that have been reported so far include hand-foot 
syndrome, fatigue, hypertension, anorexia, febrile neutro-
penia, and pulmonary embolism. No grade 4 SAEs have 
been recorded so far.
The clinical trials of anti-VEGF agents are summarized 
in Table 3.
Mammalian target of rapamycin 
(mTOR)
Mammalian target of rapamycin (mTOR) serine-
threonine kinase is a downstream component of the 
  phosphatidylinositol 3-kinase/Aktkinase signaling pathway. 
This pathway regulates cellular metabolism and growth 
by acting as a cellular sensor for nutrients and growth 
factors. Upregulation of this pathway has been associated 
with worse prognosis in GC98 and also in squamous cell 
esophageal cancer.99 It has been postulated to contribute 
to chemotherapy resistance.100
Everolimus (Afinitor®, Novartis, Basel, Switzerland) 
blocks the mTOR pathway by forming a complex with the 
immunophilin FK506-binding protein-12. It is currently FDA 
approved for use in progressive neuroendocrine tumors of 
pancreatic origin and advanced renal cell carcinoma after 
failure of first-line sunitinib or sorafenib. Phase I data exist 
showing marked tumor response to everolimus in esophageal 
carcinoma;101 however, as yet no Phase II data are available 
investigating its use in esophageal cancer.
More progress has been made investigating the use of 
everolimus in metastatic gastric cancer. Doi et al102 reported a 
Phase II study of everolimus in this population with   promising 
results. Fifty-three patients who had previously received 
chemotherapy for metastatic GC received   everolimus. There 
were no complete or partial responses in this trial; however, 
45% of patients had a reduction in tumor size from baseline. 
Furthermore, OS was 10.1 months, which compares favorably 
with other single-agent trials,103,104 where OS ranges from 3.5 
to 7.2 months and combination trials,105,106 where OS ranges 
from 6.0 to 10.7 months. Recently, the results of the Phase III 
GRANITE-1study evaluating the role of everolimus in pre-
viously treated advanced GC patients were released at the 
ASCO GI 2012 meeting, concluding that everolimus mono-
therapy does not significantly improve the OS and PFS.107 
A total of 656 patients with advanced GC were randomized 
in 2:1 fashion to everolimus/best supportive care compared 
with placebo/best supportive care. The OS was 5.39 months 
with everolimus compared with 4.34 months in the placebo 
arm (HR, 0.90; 95% CI, 0.75–1.08; P = 0.1244). Median PFS 
per local investigator assessment was 1.68 and 1.41 months 
with everolimus and placebo respectively (HR, 0.66; 95% CI, 
0.56–0.78; P , 0.0001). The ORR was also not very encour-
aging (4.5% with everolimus versus 2.1% with placebo).
Novel targets
Marimastat
Marimastat is an MMP inhibitor and has been tested in 
a Phase III study (compared with placebo) including 
369 patients with inoperable/metastatic GC/GEJ AC.108 
There was a small but statistically significant improvement 
in OS (160 versus 138 days; P = 0.02) and 2-year survival 
(9% versus 3%), favoring the marimastat arm. However, this 
drug’s further development has stopped.
Foretinib
Another novel target, c-MET, which is a receptor for 
  hepatocyte growth factor is currently under evaluation.109 The 
c-MET oncogene is amplified in 10%–15% of GC, and its 
overexpression has been associated with poor prognosis.110,111 
Foretinib is an oral TKI with activity against VEGFR-2 and 
c-MET. It was evaluated at two different doses in a Phase II 
study (n = 64) involving previously treated patients with 
EGC.108 The ORR was 0%, with stable disease in 21% and 
25% of patients in each dose cohort. Amplification of c-MET 
was lower than expected (5%) in this study, and future   studies 
are planned limiting the use of foretinib in patients with 
c-MET amplification only.
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Bryostatin
Bryostatin-1 is an inhibitor of protein kinase C, which plays 
a role in mediation of anti-apoptotic signals.112 Two Phase II 
studies have evaluated sequential taxol and bryostatin in 
EGC. Grade 3/4 myalgias occurred in about half of the 
patients, leading to cessation of further development of this 
drug.113,114
Cyclo-oxygenase-2 inhibitors
Cyclo-oxygenase-2 (COX-2) is an enzyme involved in the 
prostaglandin synthesis and malignant transformation of 
  Barrett’s esophagus. The use of aspirin and other nonsteroidal 
agents have been associated with lower esophageal cancer 
rates. In a meta-analysis including nine studies with more 
than 1800 patients, there was 43% risk reduction of devel-
oping esophageal cancer with these agents.115 However, the 
chemoprevention for Barrett’s esophagus trial did not find any 
difference in the primary outcome – change from baseline to 
48 weeks of therapy in the proportion of biopsy specimens 
with dysplasia in the celecoxib and placebo arms.116 The 
criticism of this study was the short treatment duration and 
follow up, but the negative results in conjunction with the 
known cardiotoxicity of COX-2 inhibitors117 makes routine 
use of these agents as chemoprevention inappropriate.
Other novel agents
Studies are ongoing with other novel agents targeting insulin-
like growth factor receptor (IGF), its ligand IGF-1, and 
telomerase enzyme.118
Conclusion
In conclusion, the prognosis associated with advanced EGC 
remains poor. Various molecular targeted therapies have been 
evaluated in clinical trials with trastuzumab now becoming 
a standard treatment option for patients with Her2-positive 
EGC. Further research in this field is urgently needed to 
improve outcomes for patients.
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